Peter A. Zimmerman

Peter A. Zimmerman

Auto-generated profile, based on publicly available information

Peter A. Zimmerman

Professor of International Health, Genetics and Biology, The Center for Global Health & Diseases, Case Western Reserve University, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2011 in Nature Communications
Verified
Journal Article
Open access
RHRosalind E. Howes
Rosalind E. Howes
APAnand P. Patil
Anand P. Patil
FPFrédéric B. Piel
Frédéric B. Piel
ONOscar A. Nyangiri
Oscar A. Nyangiri
CKCaroline Kabaria
Caroline Kabaria
SHSimon Hay
Simon Hay
Blood group variants are characteristic of population groups, and can show conspicuous geographic patterns. Interest in the global prevalence of the Duffy blood group variants is multidisciplinary, but of particular importance to malariologists due to the resistance generally conferred by the Duffy-negative phenotype against Plasmodium vivax infection. Here we collate an extensive geo-database of surveys, forming the evidence-base for a multi-locus Bayesian geostatistical model to generate global frequency maps of the common Duffy alleles to refine the global cartography of the common Duffy variants. We show that the most prevalent allele globally was FY*A, while across sub-Saharan Africa the predominant allele was the silent FY*B(ES) variant, commonly reaching fixation across stretches of the continent. The maps presented not only represent the first spatially and genetically comprehensive description of variation at this locus, but also constitute an advance towards understanding the transmission patterns of the neglected P. vivax malaria parasite.

15 March 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Didier MenardDidier Menard
Didier Menard
CBCéline Barnadas
Céline Barnadas
CBChristiane Bouchier
Christiane Bouchier
CHCara Henry-Halldin
Cara Henry-Halldin
LGLaurie R. Gray
Laurie R. Gray
PZPeter A. Zimmerman
Peter A. Zimmerman
Malaria therapy, experimental, and epidemiological studies have shown that erythrocyte Duffy blood group-negative people, largely of African ancestry, are resistant to erythrocyte Plasmodium vivax infection. These findings established a paradigm that the Duffy antigen is required for P. vivax erythrocyte invasion. P. vivax is endemic in Madagascar, where admixture of Duffy-negative and Duffy-positive populations of diverse ethnic backgrounds has occurred over 2 millennia. There, we investigated susceptibility to P. vivax blood-stage infection and disease in association with Duffy blood group polymorphism. Duffy blood group genotyping identified 72% Duffy-negative individuals ( FY*B ES /*B ES ) in community surveys conducted at eight sentinel sites. Flow cytometry and adsorption–elution results confirmed the absence of Duffy antigen expression on Duffy-negative erythrocytes. P. vivax PCR positivity was observed in 8.8% (42/476) of asymptomatic Duffy-negative people. Clinical vivax malaria was identified in Duffy-negative subjects with nine P. vivax monoinfections and eight mixed Plasmodium species infections that included P. vivax (4.9 and 4.4% of 183 participants, respectively). Microscopy examination of blood smears confirmed blood-stage development of P. vivax , including gametocytes. Genotyping of polymorphic surface and microsatellite markers suggested that multiple P. vivax strains were infecting Duffy-negative people. In Madagascar, P. vivax has broken through its dependence on the Duffy antigen for establishing human blood-stage infection and disease. Further studies are necessary to identify the parasite and host molecules that enable this Duffy-independent P. vivax invasion of human erythrocytes.

4 February 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ELEnmoore Lin
Enmoore Lin
BKBenson Kiniboro
Benson Kiniboro
LGLaurie Gray
Laurie Gray
SDStuart Dobbie
Stuart Dobbie
LRLeanne Robinson
Leanne Robinson
IMIvo Mueller
Ivo Mueller
Where P. vivax and P. falciparum occur in the same population, the peak burden of P. vivax infection and illness is often concentrated in younger age groups. Experiences from malaria therapy patients indicate that immunity is acquired faster to P. vivax than to P. falciparum challenge. There is however little prospective data on the comparative risk of infection and disease from both species in young children living in co-endemic areas. A cohort of 264 Papua New Guinean children aged 1-3 years (at enrolment) were actively followed-up for Plasmodium infection and febrile illness for 16 months. Infection status was determined by light microscopy and PCR every 8 weeks and at each febrile episode. A generalised estimating equation (GEE) approach was used to analyse both prevalence of infection and incidence of clinical episodes. A more pronounced rise in prevalence of P. falciparum compared to P. vivax infection was evident with increasing age. Although the overall incidence of clinical episodes was comparable (P. falciparum: 2.56, P. vivax 2.46 episodes / child / yr), P. falciparum and P. vivax infectious episodes showed strong but opposing age trends: P. falciparum incidence increased until the age of 30 months with little change thereafter, but incidence of P. vivax decreased significantly with age throughout the entire age range. For P. falciparum, both prevalence and incidence of P. falciparum showed marked seasonality, whereas only P. vivax incidence but not prevalence decreased in the dry season. Under high, perennial exposure, children in PNG begin acquiring significant clinical immunity, characterized by an increasing ability to control parasite densities below the pyrogenic threshold to P. vivax, but not to P. falciparum, in the 2nd and 3rd year of life. The ability to relapse from long-lasting liver-stages restricts the seasonal variation in prevalence of P. vivax infections.

23 November 1999 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PZPeter A. Zimmerman
Peter A. Zimmerman
IWIan John Woolley
Ian John Woolley
GMGodfred L. Masinde
Godfred L. Masinde
SMStephanie M. Miller
Stephanie M. Miller
DMDavid T. McNamara
David T. McNamara
JKJames W. Kazura
James W. Kazura
In Papua New Guinea (PNG), numerous blood group polymorphisms and hemoglobinopathies characterize the human population. Human genetic polymorphisms of this nature are common in malarious regions, and all four human malaria parasites are holoendemic below 1500 meters in PNG. At this elevation, a prominent condition characterizing Melanesians is α+-thalassemia. Interestingly, recent epidemiological surveys have demonstrated that α+-thalassemia is associated with increased susceptibility to uncomplicated malaria among young children. It is further proposed that α+-thalassemia may facilitate so-called “benign”Plasmodium vivaxinfection to act later in life as a “natural vaccine” against severePlasmodium falciparummalaria. Here, in aP. vivax-endemic region of PNG where the resident Abelam-speaking population is characterized by a frequency of α+-thalassemia ≥0.98, we have discovered the mutation responsible for erythrocyte Duffy antigen-negativity (Fy[a−b−]) on theFY*Aallele. In this study population there were 23 heterozygous and no homozygous individuals bearing this new allele (allele frequency, 23/1062 = 0.022). Flow cytometric analysis illustrated a 2-fold difference in erythroid-specific Fy-antigen expression between heterozygous (FY*A/FY*Anull) and homozygous (FY*A/FY*A) individuals, suggesting a gene-dosage effect. In further comparisons, we observed a higher prevalence ofP. vivaxinfection inFY*A/FY*A(83/508 = 0.163) compared withFY*A/FY*Anull(2/23 = 0.087) individuals (odds ratio = 2.05, 95% confidence interval = 0.47–8.91). Emergence ofFY*Anullin this population suggests thatP. vivaxis involved in selection of this erythroid polymorphism. This mutation would ultimately compromise α+-thalassemia/P. vivax-mediated protection against severeP. falciparummalaria.

4 June 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
IMIvo Mueller
Ivo Mueller
SSSonja Schoepflin
Sonja Schoepflin
TSThomas A. Smith
Thomas A. Smith
KBKathryn L. Benton
Kathryn L. Benton
MBMichael T. Bretscher
Michael T. Bretscher
IFIngrid Felger
Ingrid Felger
GenotypingPlasmodium falciparumparasites in longitudinal studies provides a robust approach to estimating force of infection (FOI) in the presence of superinfections. The molecular parametermolFOI, defined as the number of newP. falciparumclones acquired over time, describes basic malaria epidemiology and is suitable for measuring outcomes of interventions. This study was designed to test whethermolFOI influenced the risk of clinical malaria episodes and how farmolFOI reflected environmental determinants of transmission, such as seasonality and small-scale geographical variation or effects of insecticide-treated nets (ITNs). Two hundred sixty-four children 1–3 y of age from Papua New Guinea were followed over 16 mo. Individual parasite clones were tracked longitudinally by genotyping. On average, children acquired 5.9 (SD 9.6) newP. falciparuminfections per child per y.molFOI showed a pronounced seasonality, was strongly reduced in children using ITNs (incidence rate ratio, 0.49; 95% confidence interval, [0.38, 0.61]), increased with age, and significantly varied within villages (P= 0.001). The acquisition of new parasite clones was the major factor determining the risk of clinical illness (incidence rate ratio, 2.12; 95% confidence interval, [1.93, 2.31]). Adjusting for individual differences inmolFOI completely explained spatial variation, age trends, and the effect of ITN use. This study highlights the suitability ofmolFOI as a measure of individual exposure and its central role in malaria epidemiology. It has substantial advantages over entomological measures in studies of transmission patterns, and could be used in analyses of host variation in susceptibility, in field efficacy trials of novel interventions or vaccines, and for evaluating intervention effects.

14 December 2010 in Malaria Journal
Verified
Journal Article
Open access
PDF file
ARAnna Rosanas-Urgell
Anna Rosanas-Urgell
DMDania Mueller
Dania Mueller
IBInoni Betuela
Inoni Betuela
CBCéline Barnadas
Céline Barnadas
JIJonah Iga
Jonah Iga
IFIngrid Felger
Ingrid Felger
Accurate diagnosis of Plasmodium infections is essential for malaria morbidity and mortality reduction in tropical areas. Despite great advantages of light microscopy (LM) for malaria diagnosis, its limited sensitivity is a critical shortfall for epidemiological studies. Robust molecular diagnostics tools are thus needed.